m6A epitranscriptomic modification of inflammation in cardiovascular disease
YS Zhang, ZY Liu, ZY Liu, LC Lin, Q Chen… - International …, 2024 - Elsevier
Cardiovascular disease is currently the number one cause of death endangering human
health. There is currently a large body of research showing that the development of …
health. There is currently a large body of research showing that the development of …
[HTML][HTML] Amalgamation of nano and 3-D printing technology: Design, optimization, and assessment
H Rana, D Chavada, V Thakkar - Annals of 3D Printed Medicine, 2024 - Elsevier
Personalized medicine is the need of today's era, as one therapy does not fit all. The study
aims to develop a novel patient-customized formulation using the integration of 3-D printing …
aims to develop a novel patient-customized formulation using the integration of 3-D printing …
Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study
A Sachdeva, A Shukla… - Indian Journal of …, 2024 - journals.sagepub.com
Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little
is known about its uses or impact in real-world practice in the Indian population. We …
is known about its uses or impact in real-world practice in the Indian population. We …
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Sacubitril-Valsartan is a first-class therapeutic agent for ARNI (Angiotensin Receptor-
Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morbidity in …
Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morbidity in …